In $94M Agreement, Royalty Pharma Acquires Royalty Interest in Entyvio

Read about Royalty Pharma's $94 million acquisition of a royalty interest in IBD therapy Entyvio from Massachusetts General Hospital’s (MGH).

Related Keywords

Massachusetts ,United States ,Andrew Lazarovitz ,Pablo Legorreta ,Robert Colvin ,Richard Moscicki ,Chris Coburn ,James Kurnick ,Crohn Colitis Foundation ,European Medicines Agency ,Drug Administration ,Committee For Medicinal Products Human Use ,Millennium Pharmaceuticals ,Royalty Pharma ,Massachusetts General Hospital ,Medicinal Products ,Human Use ,Atul Bhan ,